diagnost lead revenu growth
maintain buy rate upgrad tp
previous deriv estim base forward
earn multipl ep estim
top-lin grow
estim top line revenu growth due
acquisit st jude medic jan posit
growth aler acquisit launch alin
system boost diagnost segment sale foresight
combin abbott st jude medic increas
sale cardiovascular segment
freestyl libr hand continu drive
diabet care sale abbott achiev number import
regulatori reimburs mileston libr freestyl
libr receiv regulatori approv canada
cardiovascular neuromodul segment led sale
growth abbott compani achiev
top-lin growth y/i st jude help abbott becom
lead player medic devic adjust ep
quarter beat estim
led extraordinari growth cardiovascular segment
abbott beat consensu revenu beat estim
adjust ep beat estim
compani nameabbott laboratoriestickerabtstock ratingbuyunchangedindustri viewoverweightpositivepric feb week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideashej except ep crispidea abbott laboratori februari
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
total revenu quarter compar
increas y/i growth driven
acquisit st jude medic inc well growth
establish pharmaceut product diagnost product
segment exclud impact foreign exchang
net loss compar net incom
loss primarili due net
expens estim impact tax cut
job act tax reform ep quarter
geograph wise total sale quarter
increas y/i report basi
oper basi total intern sale
quarter increas report basi
oper basi
novemb abbott initi launch freestyl libr
continu glucos monitor cgm system avail
come factory-calibr remov need routin
fingerstick peopl diabet
vascular abbott obtain ce mark xienc sierra drug-
elut coronari stent system enhanc competit
posit categori market
guidanc abbott project full-year adjust ep
organ sale growth forecast
expect rapid diagnost contribut sale
littl forecast adjust tax rate
full year also forecast
adjust gross margin ratio around sale adjust
 invest sg expens sale
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date oct last split factor new per last split date jan inform abbott laboratori februari
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
incom statement item month end month end month end month end month end month end month end month end month end month end month end revenu total- total revenu gross selling/general/admin expens research interest expens incom net operating- unusu expens incom oper expens total- total oper oper interest incom expens net loss sale assets- net- incom incom minor interest- equiti affiliates- net incom extra account change- discontinu operations- extraordinari item- net prefer dividends- incom avail common excl extra incom avail common incl extra basic weight averag shares- basic ep exclud extraordinari items- basic ep includ extraordinari items- dilut adjustment- dilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari items- dividend per share common stock primari gross dividend common stock- net incom stock base comp expense- basic ep stock base comp expsense- dilut ep stock base comp expense- depreci supplemental- total special items- normal incom taxes- effect special item incom taxes- incom tax ex impact special items- normal incom taxes- normal incom avail common- basic normal eps- dilut normal actual annual estim annual actual quarterli februari
 short term short term account receiv trade receiv other- total receiv total prepaid current asset total current property/plant/equip total goodwil intang long term long term asset total account accru note payable/short term current port lt debt/capit current liabil total current long term capit leas obligations- total long term total defer incom minor liabil total redeem prefer stock total- prefer stock non redeem net- common stock addit paid-in capital- retain earn accumul treasuri stock equiti total total liabil sharehold share out common stock primari issue- total common share actual annual actual quarterli balanc sheet item abbott laboratori februari
month end month end month end month end month end month end month end month end income/start taxes- work oper invest item invest dividend retir stock retir debt financ exchang chang interest paid tax paid februari
cardiovascular neuromodul segment led sale growth abbott
compani achiev top-lin growth y/i st jude
help abbott becom lead player medic devic adjust
ep quarter beat estim
total revenu quarter compar
increas y/i growth driven acquisit st
jude medic inc well growth establish pharmaceut product
diagnost product segment exclud impact foreign exchang
cog quarter compar
increas y/i gross profit margin
compar decreas primarili reflect higher intang
amort expens inventori step-up amort relat st jude
 expens increas y/i compar
primarili due addit acquir st jude
sg expens increas y/i compar
increas primarili due addit
acquiredst jude medic busi well increment expens
integr st jude medic abbott exist vascular busi partial
off-set impact cost improv initi across variou abbott
function busi
ebit quarter compar
decreas y/i decreas primarili attribut increas
oper expens oper margin stood quarter
net loss compar net incom
loss primarili due net expens
estim impact tax cut job act tax reform ep
quarter
total revenu
quarter
compar
cog
quarter
compar
increas y/i
net loss
compar
net incom
loss primarili due
net expens
estim impact
tax cut job act
ep quarter
total revenu compar
increas y/i growth driven acquisit st jude
medic inc st jude medic complet januari well
growth establish pharmaceut product diagnost product
segment exclud impact foreign exchang
total revenu
compar
cog compar
increas y/i gross profit margin compar
decreas primarili reflect higher intang amort
expens inventori step-up amort relat st jude medic
sg expens
increas y/i
compar
amort cost intang asset compar
 expens increas y/i compar
primarili due addit acquir st jude medic busi
net incom
compar
ep
sg expens increas y/i compar
increas primarili due addit
acquiredst jude medic busi well increment expens
integr st jude medic abbott exist vascular busi partial
off-set impact cost improv initi across variou abbott
function busi
ebit compar decreas
y/i decreas primarili attribut increas oper expens
y/i oper margin stood
net incom compar
decreas primarili due net expens estim
impact tax cut job act tax reform record
ep
abbott oper differ segment name establish pharmaceut
product nutrit diagnost medic devic total revenu
segment quarter increas oper
basi amo busi divest first quarter
report part medic devic group
total sale quarter increas
y/i report basi oper basi total intern sale
quarter increas report basi
oper basi
total sale quarter increas y/i
report basi oper basi total intern sale
quarter increas report basi
includ sale broad line brand gener pharmaceut
total sale
quarter
increas y/i
report basi
total sale
quarter
increas y/i
report basi
total revenu
segment
increas
y/i report basi
total revenu segment increas
y/i report basi includ favor effect foreign exchang
increas oper basi sale growth quarter led
double-digit growth key emerg market total revenu
segment increas y/i report basi
sale key emerg market increas report basi quarter
includ favor effect foreign exchang increas
oper basi oper sale growth led double-digit growth across
sever geographi includ india china latin america
segment includ world-wide sale broad line adult pediatr
total revenu segment quarter increas
world-wide report basi oper basi includ
favor effect foreign exchang total revenu segment
increas report oper
world-wide pediatr nutrit sale increas report basi
quarter includ favor effect foreign exchang
increas oper basi
world-wide adult nutrit sale increas report basi
quarter includ favor effect foreign exchang
increas oper basi
segment includ world-wide sale diagnost system test blood
bank hospit commerci laboratori alternate-car test site
segment report purpos laboratori diagnost molecular
diagnost point ibi diagnost divis aggreg
report diagnost product segment
total revenu
segment quarter
increas
world-wide report basi
oper basi
report basi
quarter
sale increas
report basi quarter
total revenu segment grew quarter
report basi increas oper basi total revenu
segment increas report
oper basi
laboratori diagnost sale increas report basi
quarter includ favor effect foreign exchang
increas oper basi growth quarter led
continu above-market growth driven share gain global
molecular diagnost sale increas report basi quarter
includ favor effect foreign exchang
increas oper basi continu growth infecti diseas
test abbott core area focu molecular diagnost market
off-set plan scale test area
point diagnost sale increas report basi
quarter includ favor effect foreign exchang
increas oper basi growth led continu
adopt abbott i-stat handheld system
cardiovascular neuromodul
segment includ sale rhythm manag electrophysiolog heart
failur vascular structur heart neuromodul product
increas
report basi
quarter
point diagnost
sale increas
report basi
quarter
total revenu
cardiovascular
grew
report basi
oper basi
total revenu segment grew report basi
oper basi quarter total revenu
increas report basi increas oper
cardiovascular neuromodul world-wide sale led double-
digit growth electrophysiolog structur heart heart failur
neuromodul growth structur heart driven mitraclip
neuromodul growth led sever recent launch product
treatment chronic pain movement disord
world-wide diabet sale increas report basi
quarter includ favor effect foreign exchang
increas oper basi strong double-digit intern sale
growth led freestyl libr
cardiovascular
world-wide sale led
double-digit growth
failur
sale increas
report basi quarter
includ
favor effect
foreign exchang
increas
novemb abbott initi launch freestyl libr
continu glucos monitor cgm system avail come factory-
calibr remov need routin fingerstick peopl
januari abbott announc freestyl libr avail
approv coverag center medicar medicaid servic
octob abbott receiv fda clearanc confirm rx insert
cardiac monitor icm world first smartphone-compat icm
design help physician remot identifi cardiac arrhythmia
obtain ce mark xienc sierra newest gener compani
vascular abbott obtain ce mark xienc sierra drug-elut
coronari stent system enhanc competit posit categori
market
decemb abbott receiv fda approv magnet reson mr
condit label quadra assura quadra assura mp cardiac
resynchron therapi defibril crt-d devic fortifi
implant cardiovert defibril approv abbott
mr-condit label full suit pacemak crt-d devic
guidanc conclus
abbott project full-year adjust ep
organ sale growth forecast
expect rapid diagnost contribut sale littl
forecast adjust tax rate full year
forecast adjust gross margin ratio around sale
adjust invest sg expens sale
adjust ep
forecast compar oper sale growth
abbott wit strong sale growth quarter top-lin number grew
quarter acquisit st jude medic jan
help abbott becom medic devic leader top posit high-
acquisit aler expand abbott presenc one area
diagnost abbott initi launch alin platform instrument
integr famili next-gener diagnost system everi area
diagnost compani compet
rhythm manag abbott close mri safe product gap across
portfolio includ fda approv pacemak crtd
devic electrophysiolog compani launch ensit precis abbott
best-in-class cardiac map system abbott also launch next gener
confirm insert cardiac heart monitor europ
rais narrow
project full-year
adjust dilut ep
continu oper
forecast adjust
gross margin ratio
around sale
adjust invest
sg expens
sale
abbott initi launch
alin platform
instrument integr
famili next-gener
diagnost system everi
area diagnost
compani compet
non- reconciliait
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin fell ttm compar due increas cog
revenu growth seen ttm
ep growth ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbott laboratori februari
mrqgross mrqcog mrqsg mrqoper mrqnet mrqr sale abbott laboratori februari
invest flow
sale
mrq ratio growth yoy oper growth yoy free growth mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrqcapex salescap ex salesfre /sale abbott laboratori februari
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item abbott laboratori februari
balanc sheet item
outstand equival market properti plant properti plant issuanc prefer issuanc chang abbott laboratori februari
abbott saw good growth price-to-earnings dip surpass price-to-earnings band
tremend perform due acquisit st jude medic jan abbott even
broke price-to-earnings barrier continu strong perform
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held insid share held institut mutual fund float held institut mutual fund institut hold direct holder form daniel mile michael stephen eric thoma richard john robert brian institut holdersholdershar report outvaluevanguard group inc capit research global wellington manag compani massachusett servic price row associ northern trust america top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard vanguard specialized-health spdr etf vanguard institut fund-institut vanguard specialized-dividend appreci growth fund america mf seri trust i-mf valu invest compani amcap februari
developmentsabbott revolutionari continu glucos monitor freestyl libr avail medicar patientsabbott announc freestylelibr system compani revolutionari new continu glucos monitor cgm system avail medicar patient met code therapeut cgm system use coverag center medicar medicaid servic coverag includ medicar patient diabet use insulin meet elig criteria new fda mr-condit label approv expand abbott portfolio mri-readi devicesabbott announc food drug administr fda approv magnet reson mr -condit label quadra assura mp cardiac resynchron therapi defibril crt-d fortifi assura implant cardiovert defibril two compani widely-us high voltag medic devic approv follow recent mr-condit label approv assur mri pacemak ellips associ mri-compat lead expand abbott portfolio mri-readi devic patient indic and/or crt-d devic may need mri futur abbott launch alin h-seri integr hematolog combin speed seamless integrationabbott announc ce mark alin h-seri integr system hematolog test join alin hq stand-alone hematolog analyz obtain ce mark earlier year new alin h-seri solut integr alin hq alin hs slide maker stainer modul combin solut alin h-seri solut percent faster per current avail integr hematolog system throughput complet blood count cbc per sq abbott mitraclip approv first transcathet mitral valv repair devic japan abbott announc japan ministri labour welfar mhlw approv compani mitraclip devic treatment peopl mitral regurgit mr seriou progress heart diseas mitral valv close properli allow blood flow backward heart mr caus mani life-alt symptom left untreat ultim lead heart failur death peopl affect elderli mr incid increas age januari februari
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
ytd perform
outperform
gross margin
in-lin
industri average
dividend yield
higher
industri average
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit abbott laboratori februari
consensu view analyst trend stock
forecast higher
 averag
forward price-to-earnings
abt avgfive-year growth forecast usdgrowth high day day day estim comparisonabtindustri avg avgprice/earn yield februari
consensu view analyst trend stock
earn growth
expect
revenu growth estim
adjust ep expect
estimatescurr analyst estimatethi estim estimatepast ep growthpeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last daysn/an/an/an/a current growth ratescurr surprisescurr februari
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock hit back level first time sinc juli maintain uptrend due
recent overal market declin stock also tank last month
strong y/i revenu growth acquisit aler octob make buy abbott
acquisit st jude medic jan strong sale growth three quarter
stock rise sinc
stock reach high jan strong result given total
return last year
stock shown signific movement side last year fell previou high
juli feb rise sinc dec
stock reach all-tim high jan given total return last year
abbott seen spectacular growth stock price back st jude medic acquisit
jan boost cardiovascular segment maintain buy rate abbott
target price deriv target price forward look price-to-earnings ep
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
